FDA
-
-
-
-
-
-
-
Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight
-
-
-
-
-
-
-
HCW Biologics Reports Positive Results from Non-Human Primate Study for Its Proprietary Second-Generation T-Cell Engager Program
-
-
-
-
-
-
-
HCW Biologics (HCWB) Announces Positive Results of Studies of Proprietary Compound, HCW9206 and Availability for Commercialization
-
-
-
-
-
-
-
HCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights
-
-
-
-
-
-
-
U.S. Patent Issued to HCW Biologics for Foundational Platform Technology
-
-
-
-
-
-
-
HCW Biologics’ CEO Hing C. Wong, Ph.D., to be Featured Speaker at the Third Annual International Conference on Cell and Experimental Biology 2022
-
-
-
-
-
-
-
Masonic Cancer Center at the University of Minnesota Receives FDA Clearance to Proceed with Phase 1 Clinical Trial in Solid Tumors for HCW9218, HCW Biologics’ Novel Bifunctional Fusion Protein
-
335,292 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


